Frequently Asked Questions (FAQ) - WHO Pilot Procedure for Prequalification of Biotherapeutic Products: rituximab and trastuzumab

This is the first Q&A on biotherapeutic/similar biotherapeutic products (BTP/SBP) based on the experience of rituximab and trastuzumab applications in the ongoing BTP/SBP pilot prequalification project. This first Q&A, which will be expanded as the project moves forward, focuses on the issues surrounding the choice of RBPs (reference biotherapeutic products).